Summary of Key Points from the Conference Call Industry Overview - **Sector**: China's healthcare sector, specifically focusing on Biotech/Pharma and CRO/CDMO segments - **Trend**: Transitioning from "go-global beta" to "visibility-driven alpha" as the sector shows robust performance in 2025, driven by emerging assets expanding globally [1][2] Core Insights - **Investment Strategy Shift**: Investors are moving from beta trades based on licensing expectations to focusing on tangible execution and visibility into key data readouts and earnings delivery for 2026 [1][2] - **CRO/CDMO Outlook**: Positive outlook for CDMOs due to accelerated growth, strong product cycles, and reasonable valuations. Upgrades for WuXi AppTec and WuXi XDC to "Buy" [2][11] - **Biotech/Pharma Selectivity**: A more selective approach is advised, favoring companies with validated early data and realistic deal expectations. Preferred stocks include Kelun Biotech, Henlius, and Hansoh [2][7] - **MedTech Neutral Stance**: Cautious outlook on MedTech, with a recommendation to buy AngelAlign and Weigao, while maintaining a neutral stance overall [2][7] - **Healthcare Services Caution**: Downgraded outlook for healthcare services due to cost control measures and weak consumption cycles, with downgrades for Hygeia and Jinxin [2][7] Emerging Technologies - **AI and New Modalities**: Anticipated advancements in AI within healthcare and a strengthening of China's leadership in new modalities such as next-gen ADCs and innovative oligonucleotide medicines [3][7] - **Surgical Robotics**: 2026 is expected to be pivotal for surgical robotics commercialization, driven by new national billing rules [3] Financial Metrics and Projections - **Earnings Estimates**: EPS estimates for Chinese CDMOs/CROs revised up by 3%-4% for FY26-27 due to improved earnings visibility [11] - **Capex Normalization**: Capital expenditure is returning to growth levels, focusing on high-potential modalities and overseas expansion [10][21] - **Valuation Recovery**: Valuations for WuXi AppTec and WuXi XDC are expected to recover modestly as visibility improves, although they still trade at a discount compared to global peers [10][14] Market Dynamics - **Geopolitical Sensitivity**: Market sensitivity to geopolitical headlines has decreased, with a clearer distinction between sentiment risk and actual business impact [10][27] - **Outsourcing Trends**: Despite geopolitical uncertainties, outsourcing rates are expected to rise, driven by cost efficiency and access to specialized technologies [28] Key Risks and Considerations - **Biosecure Act Impact**: The Biosecure Act's implications are being closely monitored, with expectations that any structural reallocation of outsourcing away from China will be gradual [42] - **Client Behavior**: Client concerns regarding the Biosecure Act have diminished, with high retention rates noted for WuXi's services [13] Conclusion - The healthcare sector in China is poised for a significant transformation as it shifts towards visibility-driven investments. Key players in the CDMO and Biotech/Pharma segments are expected to benefit from improved earnings visibility and a supportive funding environment, while caution remains in MedTech and healthcare services due to ongoing economic pressures.

Core Viewpoint - WuXi Biologics has been awarded the Platinum Medal by EcoVadis for the third consecutive year, recognizing its strong performance in sustainability and ESG practices [1][2]. Group 1: Sustainability Achievements - WuXi Biologics is ranked in the top 1% of over 150,000 companies evaluated globally, reflecting its robust ESG policies and performance outcomes validated by external stakeholders [2]. - The company has set near-term and net-zero GHG emissions reduction targets approved by the Science Based Targets initiative (SBTi), positioning it as a leader in the industry [3]. - WuXi Biologics launched a Green CRDMO White Paper detailing its green innovation technologies and showcasing significant carbon reductions achieved through its operations [4]. - The company has achieved ISO 20400 Sustainable Procurement certification, promoting sustainability principles in procurement practices [5]. Group 2: Leadership and Commitment - Dr. Chris Chen, CEO of WuXi Biologics, emphasized the company's commitment to advancing sustainability capabilities and enabling partners to meet their ESG goals [6]. - The achievement of the EcoVadis Platinum Medal reinforces global clients' confidence in WuXi Biologics' reliability and commitment to sustainability and compliance standards [7]. - WuXi Biologics actively participates in initiatives like the United Nations Global Compact and has received numerous recognitions, including an MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices [8]. Group 3: Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end solutions for biologics [9]. - The company employs over 12,000 skilled professionals across multiple countries and supports 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing as of December 31, 2025 [10]. - WuXi Biologics integrates ESG responsibilities into its business strategy and aims to be a leader in the biologics CRDMO sector, utilizing next-generation biomanufacturing technologies [11].

Core Viewpoint - WuXi Biologics has entered into a license and research service agreement with Vertex Pharmaceuticals for the development of a trispecific T-cell Engager aimed at treating B-cell mediated autoimmune diseases [1][2]. Group 1: Agreement Details - Vertex Pharmaceuticals will have exclusive global rights to develop and commercialize the trispecific T-cell Engager at the preclinical stage [2]. - WuXi Biologics will receive an upfront payment and is eligible for additional milestone payments related to development, regulatory approvals, and sales, along with royalty payments [2]. Group 2: Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics from concept to commercialization [4]. - The company employs over 12,000 skilled professionals across multiple countries, including China, the United States, Ireland, Germany, and Singapore, and is currently supporting 945 integrated client projects, with 74 in Phase III and 25 in commercial manufacturing as of December 31, 2025 [5]. Group 3: Commitment to Sustainability - WuXi Biologics emphasizes sustainability as a key component of long-term business growth, focusing on green technology innovations to provide advanced Green CRDMO solutions [6]. - The company is dedicated to achieving excellence in Environment, Social, and Governance (ESG) practices and collaborates with stakeholders to promote positive social and environmental impacts [6].

Investment Rating - The report indicates a positive outlook for China's biopharma sector, highlighting its transition into a more mature phase characterized by self-sufficiency and innovation [3]. Core Insights - China's biopharma sector is increasingly self-sufficient, supported by domestic funding and innovation, leading to a competitive edge in early-stage asset generation [3]. - The outlicensing market in China is expected to remain active, expanding into new therapeutic areas beyond oncology [3]. - Despite a pullback from non-domestic venture capital, domestic funding is reinforcing a self-reliant ecosystem in China's biopharma landscape [3]. - The report emphasizes that US restrictions may disrupt US biopharma innovation more than they will slow China's progress [3]. Summary by Sections Internal Dynamics of China's Biopharma Landscape - China's biopharma ecosystem is evolving from a generics powerhouse to a leader in next-generation therapeutics, supported by efficient clinical-trial infrastructure [5]. - The number of Investigational New Drug (IND) applications for innovative drugs increased significantly from 688 in 2019 to 2,298 in 2023 [5]. - China has adopted international standards for clinical trials, allowing companies to save 12 to 18 months in trial initiation compared to the US [5]. Global Engagement with China: Cross-Border Trends - China's licensing activity has increased, with a focus on complex biologics rather than legacy modalities [48]. - In 2025, antibodies and antibody-drug conjugates (ADCs) were the most licensed modalities, with significant deal values indicating their strategic importance [50][52]. - The report notes a trend of US and EU biopharma companies establishing centers of excellence in China to leverage local innovation [56][59]. Looking Ahead to 2026: Risks, Opportunities, and Geopolitical Trajectories - The BIOSECURE Act may introduce friction in cross-border collaborations but is primarily focused on downstream execution rather than early-stage asset generation [74]. - Despite potential disruptions, the demand for early-stage assets is expected to remain strong, particularly in precision oncology and cell and gene therapy [71][73]. - The report suggests that China's early-stage asset advantage is likely to persist due to rising US costs and funding constraints [74].

Summary of Key Points from the Conference Call Industry Overview - **China Equity Strategy**: The 2026 JPM China Opportunity Forum highlighted a constructive outlook on China equities, emphasizing thematic trades such as leading exporters, beneficiaries of AI infrastructure capital expenditure, anti-involution strategies, K-shaped consumption recovery, and property market upside optionality [2][7]. Core Insights - **AI Ecosystem**: The memory and ESS (Energy Storage Systems) sectors are benefiting from global AI capital expenditure demand. Notable trends include a memory up-cycle and rising localization. However, consumer electronics and automotive sectors are facing component cost increases and lower trade-in subsidies year-on-year [6][14]. - **Anti-involution Strategies**: Companies like H World and Atour are shifting to rational pricing strategies to enhance market share. Home appliance brands are focusing on innovation rather than price cuts. The solar industry is also expected to see continued anti-involution efforts [6][31]. - **Consumption Trends**: Leading brands are innovating and optimizing to counteract soft domestic demand, with a focus on overseas growth. The "Liberation Day" in April 2025 is noted as a potential trigger for a future recovery in consumer confidence [6][29]. - **Healthcare Sector**: Drug innovation is a key growth driver for pharmaceutical companies, with a focus on launching new drugs and expanding into overseas markets. Healthcare service providers are gradually recovering, aided by technology upgrades [35][38]. - **Humanoid Robots**: China leads in global humanoid robot shipments, driven by government orders. The sector faces challenges in commercialization and scalability, but industrial applications are expected to show strong potential [40][41]. Important Data Points - **Smartphone Market**: Global smartphone shipments are expected to decline by 0.9% in 2026, with iPhones projected to outperform Android devices. JPM forecasts iPhone EMS builds at 251 million units for 2025, a 6% year-on-year increase [14][15]. - **Automotive Sales**: A slow start for passenger vehicle sales in 2026 is anticipated, with a forecasted decline of 24-29% quarter-on-quarter in Q1 2026 [15]. - **Energy Storage Systems**: Global ESS battery shipments are projected to grow over 40% to approximately 900 GWh in 2026, driven by policy momentum in China and strong orders from Europe [19]. - **Semiconductor Market**: The semiconductor industry is expected to see divergent dynamics, with consumer electronics facing softness while memory and foundry segments show strength. Average DRAM pricing is forecasted to increase by approximately 60% year-on-year in 2026 [20][21]. Company-Specific Insights - **Top Picks**: J.P. Morgan's preferred companies include Zhongji Innolight, NAURA, and CATL, among others, with various ratings and market caps provided [8][10][11][13]. - **Healthcare Innovations**: Companies like Hansoh are targeting over 80% of revenue from innovative medicines by FY25, with a robust pipeline in oncology and diabetes [35][37]. Additional Considerations - **Cost Management**: Companies are overcoming upward cost pressures through process optimization and effective cost pass-through strategies in export markets [34]. - **Global Expansion**: Chinese brands are increasingly building capacity and expanding distribution in emerging markets, with notable investments in ASEAN production bases [33]. This summary encapsulates the key insights and data points from the conference call, providing a comprehensive overview of the current landscape and future outlook for various sectors within the Chinese market.

Core Viewpoint - WuXi Biologics and Sinorda Biomedicine have announced a strategic collaboration to develop and manufacture SND006, a novel bispecific antibody aimed at treating inflammatory bowel disease (IBD) and other autoimmune diseases [1][2]. Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics from concept to commercialization [4]. - The company employs over 12,000 skilled professionals across multiple countries, including China, the United States, Ireland, Germany, and Singapore [5]. - As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, with 74 in Phase III and 25 in commercial manufacturing [5]. Collaboration Details - Under the agreement, Sinorda Biomedicine will utilize WuXi Biologics' expertise in biologics development to advance SND006's preclinical studies and clinical supply, expediting the Investigational New Drug (IND) application process [2]. - Sinorda Biomedicine has completed in vitro functional validation studies for SND006 and plans to submit IND applications to the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) in 2026 [2]. Future Prospects - The collaboration aims to expand further into Sinorda Biomedicine's pipeline, which includes multiple integrated projects from molecule discovery to clinical manufacturing [2]. - Both companies believe that this partnership will accelerate the IND filings of innovative biologics, addressing unmet medical needs in autoimmune diseases [3]. Sinorda Biomedicine Overview - Established in 2010, Sinorda Biomedicine focuses on the R&D and industrialization of innovative drugs for digestive tract diseases, tumor immunity, and autoimmune diseases [8][9]. - The company has successfully commercialized its self-developed drug for gastric acid-related diseases and has ongoing clinical research for solid tumor treatments [10].

SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio’s pip ...

Core Insights - HanchorBio and WuXi Biologics have signed a strategic collaboration agreement to develop and manufacture next-generation bi- and multi-functional fusion programs from HanchorBio's pipeline [1][3][4] Company Overview - HanchorBio is a global clinical-stage biotechnology company focused on advancing immunotherapies for oncology and autoimmune diseases, utilizing its proprietary Fc-Based Designer Biologics (FBDB™) platform [1][8][9] - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics development and manufacturing [10][11] Collaboration Details - Under the agreement, WuXi Biologics will offer integrated services including cell line development, process and bioassay development, drug product formulation, and GMP manufacturing to support HanchorBio's innovative fusion protein portfolio [3][4] - The partnership aims to enhance clinical translation, improve CMC execution efficiency, and support scalable global development and manufacturing [3][4] Strategic Goals - HanchorBio's strategy focuses on advancing its multi-asset pipelines with speed, robustness, and capital efficiency from early clinical stages to commercialization [4][6] - The collaboration is expected to shorten development timelines and maintain flexibility across multiple clinical programs [4][6] Expertise and Capabilities - WuXi Biologics has extensive experience in complex modalities, supporting 945 projects as of 2025, with approximately 60% involving bi- and multi-specific antibodies, ADCs, and fusion proteins [5][11] - The company utilizes proprietary technology platforms to enhance speed, quality, and scalability in biologics development [5][11] Future Outlook - The partnership represents a significant step for HanchorBio in aligning discovery innovation with industrial-scale execution, advancing its oncology and autoimmune pipelines toward global clinical development [6][7]

Investment Rating - The report maintains a Neutral rating for WuXi AppTec, WuXi Biologics, and WuXi XDC, with specific target prices set at HK$122.5, HK$33.5, and HK$71.2 respectively [10][9][11]. Core Insights - The Chinese CDMO market sentiment is improving, with share prices for key players up by an average of 21% year-to-date [1]. - Preliminary FY25 results for WuXi AppTec, WuXi XDC, and Pharmaron were broadly in line or slightly ahead of expectations, with capacity expansion progressing well in key modalities and overseas [1]. - For FY26, WuXi AppTec expects similar growth to FY25, while WuXi Biologics anticipates accelerating revenue growth [1]. - Investors are expected to focus on backlog and new order trajectories for FY25, as well as more specific guidance for FY26 regarding revenue, margins, and capital expenditures [1]. Company Summaries WuXi AppTec - FY25 preliminary revenue reached Rmb45.5 billion, representing a 15.8% year-over-year increase, exceeding prior guidance of 13%-17% [4]. - Adjusted net profit for FY25 was Rmb15.0 billion, up 41.3% year-over-year, driven by strong contributions from the TIDES segment [4]. WuXi Biologics - FY25 saw record project additions, with expectations for FY26 revenue growth to accelerate [2]. - The company reported a significant increase in new D-segment projects, reaching a record 209, with a notable contribution from bi- and multi-specific antibodies [7]. WuXi XDC - FY25 revenue was in line with expectations, and net profit was slightly above estimates [5]. - The company announced an acquisition of BioDlink to enhance capacity expansion [7]. Pharmaron - FY25 preliminary revenue was at the upper end of guidance, with adjusted net profit slightly above expectations [6]. - The company expects faster revenue growth in FY26, supported by its integrated model [7].

Core Insights - WuXi Biologics has achieved significant advancements in 2025 through its CRDMO model, enhancing its position as a preferred partner for biopharmaceutical innovators and multinational corporations [1][2] - The company reported a record high of 209 new integrated projects in 2025, bringing the total to 945, with approximately 50% of these projects originating from U.S. clients [2][8] - WuXi Biologics is focusing on complex modalities, particularly bispecific/multispecific antibodies and ADCs, which now account for nearly 50% of its total project pipeline [4][8] Project Development - The company added 23 new projects in 2025, including 6 Phase III and commercial projects, with a significant portion involving complex modalities [5] - Bispecific/multispecific antibodies and ADCs have seen a growth of approximately 30%, reaching 196 and 252 projects respectively, contributing nearly 20% of the company's revenue with over 120% year-over-year growth [4][8] Research and Innovation - WuXi Biologics' research services achieved record-breaking upfront payments and potential milestone values exceeding USD 4 billion in 2025, driven by T-cell engager deals [7] - The CD3 platform has been widely adopted in the industry, enhancing the efficacy-safety balance of bispecific antibodies [6][7] Manufacturing Capabilities - The total number of Phase III clinical and commercial manufacturing projects reached 99 in 2025, with a strong focus on operational excellence and technology leadership [11][12] - WuXi Biologics completed 28 PPQs in 2025, maintaining a success rate of over 99% and delivering more than 350 large-scale batches since 2017 [12][13] Global Expansion - The company is increasing strategic investments in the U.S. and has commenced construction of new facilities in Singapore, positioning these sites as strategic hubs within its global network [14][15] - An MOU was signed with the Qatar Free Zones Authority to establish a strategic site in Qatar, expanding WuXi Biologics' global footprint [16] Digital Innovations - WuXi Biologics has integrated digital innovations across its operations, achieving approximately 40% productivity gains and a 20% improvement in efficiency through smart manufacturing solutions [18] - The launch of the digital twin platform PatroLab aims to enhance process performance and ensure high-quality biologics manufacturing [18] Sustainability Efforts - The company has made significant strides in sustainability, earning an MSCI AAA Rating and being recognized in various sustainability indices [19][23] - WuXi Biologics is committed to driving green technology innovations and fostering positive social and environmental impacts [23] Future Outlook - In 2026, WuXi Biologics aims to build on its strong momentum with accelerated growth driven by robust research and manufacturing capabilities [20]